Overview
Connor Landgraf is co-founder and chief executive officer of Eko Health, a company dedicated to providing healthcare professionals with industry-leading digital tools to hear and understand patients’ hearts and lungs — detecting with higher accuracy, diagnosing with more confidence, and managing treatment effectively per the about page. Eko believes the ability to listen is the ability to care.
During co-founder and CEO Landgraf’s senior thesis work at the University of California, Berkeley, he observed limitations of the traditional stethoscope while interviewing cardiologists on clinical pain points and realized the need to transform the analog stethoscope into a smart device detecting cardiovascular disease earlier.
Role and company
As Co-Founder and CEO, Landgraf leads Eko alongside Co-Founder and Chief Business Officer Jason Bellet and Chief Medical Officer Steven Steinhubl, MD. Landgraf also serves on Eko’s board of directors. Eko markets digital stethoscopes including CORE 500 with high-fidelity audio, full-color display with disease indication, and 3-lead ECG.
Eko’s SENSORA early disease detection platform received FDA clearance for low ejection fraction AI enabling identification in 15 seconds and EFAST foundation model clearance per company timeline on about page.
Background and career context
Eko’s about page establishes Landgraf’s founding insight during UC Berkeley senior thesis cardiologist interviews — connecting academic observation to commercial product development. He brought in classmates Tyler Crouch and Jason Bellet; they participated in accelerator programs where Eko was born per company history.
Landgraf’s CEO tenure spans from first FDA-cleared digital stethoscope generation through 3M Littmann CORE partnership and AI-supported heart disease detection clearances.
Company-building or leadership context
Landgraf co-founded Eko in 2013, debuting Eko CORE Gen 1 as first FDA-cleared stethoscope functioning as both analog and digital. Subsequent products added single-lead and 3-lead ECG, active noise cancellation, and AI analysis software with FDA clearance for heart disease detection. American Medical Association granted Category III CPT code for SENSORA platform per about timeline.
Eko Cares program donates up to $200,000 worth of products annually to underserved communities — reflecting Landgraf’s stated focus on heart disease disproportionately impacting vulnerable populations.
Public milestones
2013: Eko founded by Connor Landgraf with Tyler Crouch and Jason Bellet. 2015: Eko CORE Gen 1 FDA-cleared. 2017: DUO ECG + digital stethoscope. 2020: Eko Analysis Software FDA clearance for AI-supported heart disease detection. 2023: Low EF FDA clearance — 15-second identification. EFAST FDA clearance as first foundation model for cardiovascular AI. Category III CPT code for SENSORA.
Landgraf is Co-Founder and CEO on ekohealth.com/pages/about-us reviewed July 10, 2026.
Why their work matters
Eko under Landgraf proves the stethoscope — medicine’s oldest device — can become an AI edge sensor detecting heart failure signs primary care physicians miss without echocardiography referral. CPT coding for SENSORA gives reimbursement pathway primary care adoption requires beyond consumer device sales.
For healthcare AI readers, Eko is cardiovascular edge AI distinct from hospital imaging platforms but complementary to Anumana’s ECG-based low EF detection.
Sources and references
Primary sourcing: Eko Health About Us page with company timeline, reviewed July 10, 2026.
- Eko Health — About Us (ekohealth.com)
Berkeley thesis origin and FDA milestones from Eko official about page only.
Eko about page documents Eko Cares donating up to $200,000 annually in products to underserved U.S. and international communities where heart disease disproportionately impacts vulnerable populations — a social mission Landgraf’s CEO leadership pairs with FDA-cleared low ejection fraction detection enabling 15-second identification at point of care. 3M Littmann CORE partnership per company timeline shows Landgraf licensing digital stethoscope innovations to incumbent incumbents.
Eko leadership includes Co-Founder and CBO Jason Bellet and CMO Steven Steinhubl, MD, on executive roster and board per about page. EFAST FDA clearance as first foundation model for cardiovascular AI and Category III CPT code for SENSORA platform give Landgraf reimbursement pathways primary care adopters require beyond device hardware sales alone.